Literature DB >> 2644582

The Disability Status Scale for multiple sclerosis: apologia pro DSS sua.

J F Kurtzke1.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2644582     DOI： 10.1212/wnl.39.2.291

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences.

Authors:  M L Gawne-Cain; J I O'Riordan; A Coles; B Newell; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

2.  Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway.

Authors:  R Midgard; T Riise; H Nyland
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

3.  Problems with rating scales for multiple sclerosis: a novel approach--the CAMBS score.

Authors:  C J Mumford; A Compston
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

4.  Paradoxical puborectalis contraction is a feature of constipation in patients with multiple sclerosis.

Authors:  Y W Chia; K P Gill; J S Jameson; A D Forti; M M Henry; M Swash; P J Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

5.  The Functional Limitations Profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis.

Authors:  J Hutchinson; M Hutchinson
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

6.  Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS).

Authors:  D Delgado; L Canham; N Cotterill; D Cottrell; M J Drake; K Inglis; D Owen; P White
Journal:  BMC Neurol       Date:  2017-03-27       Impact factor: 2.474

7.  Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data.

Authors:  Elena Andretta; Enrico Finazzi Agrò; Massimiliano Calabrese; Luca Orecchia; Antonietta Furlan; Cristina Zuliani
Journal:  Ther Adv Urol       Date:  2022-09-24

8.  Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).

Authors:  Marcus J Drake; Luke Canham; Nikki Cotterill; Debbie Delgado; Jenny Homewood; Kirsty Inglis; Lyndsey Johnson; Mary C Kisanga; Denise Owen; Paul White; David Cottrell
Journal:  BMC Neurol       Date:  2018-08-06       Impact factor: 2.474
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.